Inhibitors of HSPs, particularly of HSP90 and HSP27, are currently being tested in clinical trials as chemo- and radio-sensitizing agents, in many different cancer therapy protocols (reviewed in refs. 5, 46, 47). Here, HSP90AA1 is linked to cancer.